July 8, 2024 10:50 AM EDTUpdated 11:15 AM
R&D

Hill­e­Vax's stock tum­bles af­ter Phase 2b norovirus vac­cine fails in in­fants

Katherine Lewin

News Reporter

Take­da spin­out Hill­e­Vax’s stock $HLVX sunk over 85% on Mon­day morn­ing af­ter the com­pa­ny an­nounced its norovirus vac­cine can­di­date failed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

RSV vac­cines off to a slug­gish start in US this sea­son, with vol­umes be­hind 2023

EMA re­views hair loss prod­ucts fol­low­ing con­cerns about sui­ci­dal thoughts

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times